Vytorin is one tablet that combines two cholesterol-lowering drugs-simvastatin (Zocor), a statin made by Merck & Co., and ezetimibe (Zetia), made by Schering-Plough Pharmaceuticals-to help lower bad cholesterol (low-density lipoprotein, or LDL) further. Simvastatin works in the liver to prevent the formation of cholesterol (as do all statin medications), while ezetimibe works by preventing the absorption of cholesterol from the intestine.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg.
Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.
Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.
The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg.
Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.
According to SDI’s recently released 2009 Ranking Tables Study, Merck’s sales representatives were ranked second by cardiologists, a noteworthy increase from sixth place in 2008. Pfizer was ranked first by cardiologists. Schering-Plough, AstraZeneca, and Novartis rounded out the top five, finishing third, fourth, and fifth, respectively.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Schering Corporation and MSP Singapore Company in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg. This product is the generic version of Vytorin® Tablets, a cholesterol treatment.
Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8 months, with further improvement seen at the end of the study (14 months).
Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.
Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.
Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.
Officials for Pfizer, Johnson & Johnson, Merck and Schering-Plough on Thursday will testify at a House Energy and Commerce Oversight and Investigations Subcommittee hearing that Democrats hope will "lay the groundwork for future legislation to tighten controls on drug marketing," the Wall Street Journal reports.
Representatives of health care marketing firms, patient advocacy groups and pharmaceutical companies this week are in Washington, D.C., to express support for loosening rules regarding drug companies' ability to market medications for off-label uses, the Wall Street Journal reports (Mundy, Wall Street Journal, 4/18).
Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.
Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company.
Researchers say a high dose of a cholesterol-lowering statin drug can reverse the build-up of plaque in coronary arteries.
Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies' pharmaceutical resources while maintaining each company's own strategic interests.
Merck/Schering-Plough Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved VYTORIN™ (ezetimibe/simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.